Literature DB >> 10335860

Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation.

Y H Ni1, M H Chang, P J Chen, H Y Hsu, T W Lu, K H Lin, D T Lin.   

Abstract

To elucidate the role of host immune status in the evolution and complexity of hepatitis C virus (HCV) quasispecies, three chronic HCV-infected patients who underwent bone marrow transplantation (BMT) were studied. The three transplanted patients' sera were sampled at pre-BMT, 3 months after BMT, and 12 months after BMT and the nucleotide diversity and substitution of the hypervariable region (HVR) of HCV quasispecies were analyzed. The nucleotide diversity was high at the pre-BMT period (28.2-43.4 x 10(-2) nucleotide difference/site). HVR of HCV quasispecies then became homogeneous in the first 3 months after BMT (0.11-6.40 x 10(-2) nucleotide difference/site). The nucleotide diversity of HVR at 12 months after BMT of all three patients was higher than that of 3 months after BMT but still lower than that of pre-BMT (2.09-6.40 x 10(-2) nucleotide difference/site). The analysis on nucleotide substitution rate showed a higher value between pre-BMT and 3 months after BMT (0.624-0.708 nucleotide difference/site per year) than that between 3 months and 12 months after BMT (0.072-0.127 nucleotide difference/site per year). HCV RNA titer decreased when the host had a low white cell count and increased accordingly. It was concluded that the evolution of HVR of HCV quasispecies related to the immune status of the host during BMT: after immunosuppression, an initial increase of viral populations was followed by the emergence of a dominant strain while the quasispecies gradually recovered as the immunity of the host gained its competence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335860     DOI: 10.1002/(sici)1096-9071(199906)58:2<132::aid-jmv6>3.0.co;2-v

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Limited Variation in BK Virus T-Cell Epitopes Revealed by Next-Generation Sequencing.

Authors:  Malaya K Sahoo; Susanna K Tan; Sharon F Chen; Beatrix Kapusinszky; Katherine R Concepcion; Lynn Kjelson; Kalyan Mallempati; Heidi M Farina; Marcelo Fernández-Viña; Dolly Tyan; Paul C Grimm; Matthew W Anderson; Waldo Concepcion; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

4.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

5.  Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).

Authors:  Tomasz Laskus; Jeffrey Wilkinson; Roksana Karim; Wendy Mack; Marek Radkowski; Marina deGiacomo; Jonathan Nasseri; Zhi Chen; Jiaao Xu; Andrea Kovacs
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

6.  Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Authors:  Jennifer M Babik; Mark Holodniy
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.

Authors:  Iwona Bukowska-Ośko; Agnieszka Pawełczyk; Karol Perlejewski; Natalia Kubisa; Kamila Caraballo Cortés; Magdalena Rosińska; Rafał Płoski; Maria Fic; Justyna Kaźmierczak; Marta Popiel; Piotr Ząbek; Andrzej Horban; Marek Radkowski; Tomasz Laskus
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 8.  The past, present and future of neutralizing antibodies for hepatitis C virus.

Authors:  Jonathan K Ball; Alexander W Tarr; Jane A McKeating
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.